BioCentury
ARTICLE | Clinical News

Amgen's trebananib misses Phase III OS endpoint

November 5, 2014 2:46 AM UTC

Amgen Inc. (NASDAQ:AMGN) reported that trebananib failed to improve overall survival among recurrent platinum-resistant ovarian cancer patients in the Phase III TRINOVA-1 study. The compound missed the top-line secondary endpoint of statistically significant improvement of OS.

Amgen reported in June 2013 that trebananib met the study's primary endpoint, improving median progression-free survival (PFS) vs. placebo plus paclitaxel (7.2 vs. 5.4 months, p<0.001) ...